

Supplementary Figure 1 S-plot of serum profile of control group and model group scanned by positive ion mode and negative ion mode. (OPLS-DA).

Note: A:In the positive ion mode, B: In the negative ion mode; Con: the sham group, Mod: the model group



Supplementary Figure 2 VIP-plot of serum profile of control group and model group scanned by positive ion mode and negative ion mode. (OPLS-DA)

Note: A:In the positive ion mode, B: In the negative ion mode; Con: the sham group, Mod: the model group





Supplementary Figure 3 Content changes of potential biomarkers in ECB model serum by positive ion mode. Note:  $\triangle P < 0.05$ ,  $\triangle \triangle P < 0.01$ , compared with control group. Con: the sham group, Mod: the model group.



Supplementary Figure 4 Summary of network pathway analysis with MetPA software

1: Phenylalanine, tyrosine and tryptophan biosynthesis; 2: Phenylalanine metabolism; 3: Tryptophan metabolism; 4: Glycerophospholipid metabolism; 5: Arachidonic acid metabolism; 6: Aminoacyl-tRNA biosynthesis.



Supplementary Figure 5 Score plot of serum profile after oral administration of PF scanned by positive ion mode (A) and negative ion mode (B). (Data were analyzed by PLS-DA). Con: the sham group, Mod: the model group, GY4: the PF group



Supplementary Figure 6 Content changes of potential biomarkers of the rats in PF group by positive ion mode. Note: \*P<0.05, \*\*P<0.01, compared with the model group. Con: the sham group, Mod: the model group, GY4: the PF group.

		Suppleme			bioinarkers in positive and neg		
No.	Rt (min)	Actual Mass	[M-H]-/[M+H]+	Proposed Composition	PostulatedIdentity	MS/MS fragment ion (m/z)	
						166.0869[M+H] <sup>+</sup>	
1	1.36	165.0789	$[M+H]^{+}$	$C_{9}H_{11}NO_{2}$	L-Phenylalanine	151.0489[M+H-NH] <sup>+</sup>	
			LJ	5 II 2	5	120.0823[M+H-CH <sub>2</sub> O <sub>2</sub> ] <sup>+</sup>	
						203.08327[M-H]-	
				~		188.9841[M-H-H2N]-	
2	1.73	204.0898	[M-H]-	C11H12N2O2	L-Tryptophan	160.0454[M-H-CHO2]-	
						130.0694[M-H-C2H5NO2]-	
						116.0563[M-H-C3H7NO2]-	
						178.0504[M-H]-	
3	2.20	179.0582	[M-H]-	C9H9NO3	Hippuric acid	162.0572[M-H-O]-	
-					rr ·····	136.0478[M-H-CO2]-	
						121.1302[M-H-C2HO2]-	
						514.293[M-H]-	
4	1 70	515 3011	[M_H]_	C26H46NO7P	$I_{VSO}PC(18.4(67.07.127.157))$	425.2906[M-H-C3H7NO2]-	
-	4.79	515.5011	[1 <b>v1-11]-</b>	020114010071	Lysol C(10.4(0 <i>L</i> , <i>JL</i> ,12 <i>L</i> ,13 <i>L</i> ))	407.2827[M-H-C7H7O]-	
						331.1941[M-H-C6H18NO3P]-	
						373.2745[M+H]+	
F	5.51	272 2664	[N.4 - 11] -	C24U2(C2		319.2409[M+H-C4H6]+	
5	5.51	372.2664	[M+H]+	C24H36O3	Cervonoyi etnanolamide	184.0763[M+H-C14H21]+	
						147.1204[M+H-C13H22O3]+	
						494.3242[M+H]+	
						311.2596[M+H-C5H14NO4P]+	
6	7.25	493.3168	[M+H]+	C24H48NO7P	LysoPC(16:1(9Z))	258.1153[M+H-C13H34NO2]+	
						184.0742[M+H-C19H36NO2]+	
						520 34[M+H]+	
						483 2494[M+H-H5O2]+	
7	7 54	519 3324	[M+H]+	C26H50NO7P	L vsoPC(18·2(97 127))	$337\ 2709[M+H-C5H14NO4P]+$	
/	7.54	517.5524		020113011071	Lyson C(10.2( <i>JE</i> ,12 <i>L</i> ))	303.0184[M+H-C13H31NO]+	
						184 0740[M+H C21H28NO2]+	
						184.0/40[MITH-C21H38NO2]T	
						200.279[M-H]-	
8	7.71	501.2855	[M-H]-	C25H44NO7P	LysoPE(0:0/20:4(8Z,11Z,14Z,17Z))	325.2380[M-H-C6H10NO3P]-	
						2/9.2303[M-H-C/H12NOSP]-	
						224.0699[M-H-C18H28O2]-	
						454.2939[M+H]+	
9	8.13	453.2855	[M+H]+	C21H44NO7P	LysoPE(16:0/0:0)	362.2845[M+H-C2H6NO3]+	
						282.2861[M+H-C2H7NO6P]+	
						184.0746[M+H-C16H32NO2]+	
						496.3404[M+H]+	
						478.3301[M+H-H2O]+	
10	8.23	495.3324	[M+H]+	C24H50NO7P	LysoPC(16:0)	313.2761[M+H-C5H14NO4P]+	
						258.1119[M+H-C10H25NO3P]+	
						184.0699[M+H-C14H35NO4P]+	
						522.3563[M+H]+	
						480.3441[M+H-C3H6]+	
11	8.64	521.3481	[M+H]+	C26H52NO7P	LysoPC(18:1(9Z))	339.2904[M+H-C6H18NO3P]+	
						258.1117[M+H-C14H34NO3]+	
						184.0680[M+H-C16H37NO4P]+	
						319.2278[M-H]-	
						269.2482[M-H-CH6O2]-	

Supplementary Table 1 MS/MS information of biomarkers in positive and negative ion mode.

12	8.99	320.2351	[M-H]-	C20H32O3	5-HETE	222.0830[M-H-C7H13]-
						179.1047[M-H-C9H16O]-
						428.0325[M+H]+
12	0.(1	401 21 (0		C221140NIO7D	$L_{\text{resc}} \mathbf{D} \mathbf{C} (15.0)$	361.2827[M+H-C5H13O3]+
15	9.01	481.3108	[M+H]+	C23H48NO/P	LysoPC(15:0)	184.0758[M+H-C13H33NO4P]+
						135.0766[M+H-C19H41NO4]+

No.	Pathway name	Total	Expected	Hits	Raw p	Impact
1	Phenylalanine, tyrosine and tryptophan biosynthesis	4	0.01712	1	0.01703	0.5
2	Phenylalanine metabolism	9	0.03852	1	0.03797	0.40741
3	Tryptophan metabolism	41	0.17546	1	0.1634	0.15684
4	Glycerophospholipid metabolism	30	0.12839	1	0.12192	0.04444
5	Arachidonic acid metabolism	36	0.15407	1	0.14475	0
6	Aminoacyl-tRNA biosynthesis	67	0.28673	2	0.02980	0

Supplementary Table 2 Result from ingenuity pathway analysis with Metaboanalyst.

Note: Total: The total number of compound in the pathway; Hits: The number of accurate matching markers in the upload data; Raw p: Original P values obtained by pathway analysis; Impact: The affected value of pathways obtained by topological analysis.

No.	Rt min	Actual Mass	Proposed Composition	Postulated Identity	Trend in ECB	PF
1	1.36	165.0789	$C_9H_{11}NO_2$	L-Phenylalanine	$\uparrow^{\Delta\Delta}$	+*
2	1.73	204.0898	$C_{11}H_{12}N_2O_2$	L-Tryptophan	${\downarrow}^{\vartriangle}$	+*
3	2.20	179.0582	C <sub>9</sub> H <sub>9</sub> NO <sub>3</sub>	Hippuric acid	$\uparrow^{\vartriangle}$	+
4	4.79	515.3011	$C_{26}H_{46}NO_7P$	LysoPC(18:4(6Z,9Z,12Z,15Z))	$\downarrow^{\vartriangle \bigtriangleup}$	+**
5	5.51	372.2664	$C_{24}H_{36}O_3$	Cervonoyl ethanolamide	$\downarrow^{\vartriangle\vartriangle}$	+
6	7.25	493.3168	$\mathrm{C}_{24}\mathrm{H}_{48}\mathrm{NO}_{7}\mathrm{P}$	LysoPC(16:1(9Z))	$\downarrow^{\vartriangle\vartriangle}$	+*
7	7.54	519.3324	$C_{26}H_{50}NO_7P$	LysoPC(18:2(9Z,12Z))	$\downarrow^{\Delta}$	-
8	7.71	501.2855	$C_{25}H_{44}NO_7P$	LysoPE(0:0/20:4(8Z,11Z,14Z,17Z))	$\downarrow^{\vartriangle\vartriangle}$	+
9	8.13	453.2855	$C_{21}H_{44}NO_7P$	LysoPE(16:0/0:0)	$\downarrow^{\vartriangle\vartriangle}$	+
10	8.23	495.3324	$C_{24}H_{50}NO_7P$	LysoPC(16:0)	$\downarrow^{\vartriangle\vartriangle}$	-
11	8.64	521.3481	$C_{26}H_{52}NO_7P$	LysoPC(18:1(9Z))	$\downarrow^{\Delta}$	+
12	8.99	320.2351	$C_{20}H_{32}O_3$	5-HETE	$\uparrow^{\vartriangle\vartriangle}$	+
13	9.61	481.3168	C <sub>23</sub> H <sub>48</sub> NO <sub>7</sub> P	LysoPC(15:0)	$\downarrow^{\bigtriangleup\bigtriangleup}$	-

Supplementary Table 3 Trend of serum potential biomarkers after oral administration of PF

Note :  $\uparrow\downarrow$  indicates that the level of the marker is increased or decreased in the urine of rats in the ECB model group ;+&- indicates that the drug has no or no effect on the marker's recall; Compared with the control group,  $\triangle P < 0.05$ ,  $\triangle \triangle P < 0.01$ ; Compared with the model group, \*P < 0.05, \*\*P < 0.01.